• About Us
  • Add Post
  • Contact
  • Contribute For Us
  • Homepage
  • Our Authors
  • Privacy Policy
What's Hot

‘It was a positive performance’: Graham Potter explains newest Chelsea setback

April 2, 2023

Israeli protests over judicial overhaul proceed regardless of Netanyahu’s pause

April 2, 2023

Crystal Palace vs Leicester end result: Dramatic profitable return for Roy Hodgson

April 2, 2023
What's Hot

‘It was a positive performance’: Graham Potter explains newest Chelsea setback

April 2, 2023

Israeli protests over judicial overhaul proceed regardless of Netanyahu’s pause

April 2, 2023

Crystal Palace vs Leicester end result: Dramatic profitable return for Roy Hodgson

April 2, 2023
Facebook Twitter Instagram
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors
Facebook Twitter LinkedIn
BusinessLendBusinessLend
  • NEWS
  • BUSINESS
  • AUTO
  • TECH
  • MONEY
  • STARTUP
  • SUCCESS STORIES
  • OTHER
    • Press Release
    • OPINION
Subscribe
BusinessLendBusinessLend
Home»Press Release»Law Offices of Howard G.
Press Release

Law Offices of Howard G.

NewsVoirBy NewsVoirMarch 15, 2023No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email





BENSALEM, Pa., March 14, 2023 (GLOBE NEWSWIRE) — Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected]

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
Class Period: October 6, 2020 – October 28, 2022
Lead Plaintiff Deadline: March 20, 2023

The complaint alleges that throughout the Class Period the defendants misrepresented to investors that, pursuant to a series of meetings and other communications between the Company and the FDA, that progress was being made that would align with the FDA’s requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omurtamab, through adequate and well-controlled studies.

Fate Therapeutics, Inc. (NASDAQ: FATE)
Class Period: April 2, 2020 – January 5, 2023
Lead Plaintiff Deadline: March 22, 2023

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (2) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (3) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
NewsVoir
  • Twitter

We are a leading corporate news distribution platform and we distribute high quality corporate and financial announcements for many large as well as upcoming brands from across India.

Related Posts

50 años después, China y España tienen una profunda amistad y logran prosperidad común

April 2, 2023

China y Singapur mejoran las relaciones para una cooperación de mayor calidad

April 2, 2023
Add A Comment

Comments are closed.

Advertisement
Editors Picks

“Super Sonu” After supplying beds, medicines and oxygen, now oxygen plant will be set up in Andhra Pradesh

May 23, 2021

Pernod Ricard Announces the Appointment of Richa Singh as CFO, Pernod Ricard South Asia and India

May 4, 2022

Yorkshire Water seeks greater than £1bn from buyers

October 13, 2022

Our relations with Azerbaijan are systematic, producing concrete outcomes – President Shavkat Mirziyoyev

November 10, 2022
Advertisement
Latest Posts

‘It was a positive performance’: Graham Potter explains newest Chelsea setback

April 2, 2023

Israeli protests over judicial overhaul proceed regardless of Netanyahu’s pause

April 2, 2023

Crystal Palace vs Leicester end result: Dramatic profitable return for Roy Hodgson

April 2, 2023

Business Lend is a platform which brings executives officers, entrepreneurs, and venture capitalist together from different sectors. We keep on connecting with our users with the help of our monthly edition carving our way slowly towards the highest readership.

Facebook Twitter Instagram LinkedIn
Must Read
  • ‘It was a positive performance’: Graham Potter explains newest Chelsea setback April 2, 2023
  • Israeli protests over judicial overhaul proceed regardless of Netanyahu’s pause April 2, 2023
  • Crystal Palace vs Leicester end result: Dramatic profitable return for Roy Hodgson April 2, 2023

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2023 BusinessLend. Designed by ThemeSphere.
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors

Type above and press Enter to search. Press Esc to cancel.